Latest News and Press Releases

NEW YORK, April 14, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for...

Did you buy SLNO common stock between March 26, 2025, and November 4, 2025? Affected Soleno Therapeutics, Inc. Investor Summary Who: Soleno Therapeutics, Inc. (NASDAQ: SLNO)What: Securities fraud...

LOS ANGELES, April 14, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Soleno Therapeutics, Inc., (“Soleno” or the “Company”) (NASDAQ: SLNO) investors off a class action on behalf of investors...

Soleno Shareholders Between March 26, 2025 and August 4, 2025 - Contact Bernstein Liebhard For More Information Regarding Shareholder Lawsuit

SLNO Investors Have Opportunity to Lead Soleno Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

LOS ANGELES, April 13, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Soleno Therapeutics, Inc., (“Soleno” or the “Company”) (NASDAQ: SLNO) investors off a class action on behalf of investors...

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Soleno (SLNO) To Contact Him Directly To Discuss Their Options If you purchased or...

NEW ORLEANS, April 09, 2026 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until May 5, 2026 to file lead plaintiff applications in a...

Soleno Shareholders Between March 26, 2025 and August 4, 2025 - Contact Bernstein Liebhard For More Information Regarding Shareholder Lawsuit

The Soleno complaint alleges that Soleno Phase 3 clinical trial program for DCCR had downplayed, misrepresented, and/or concealed safety concerns.